These are the sources and citations used to research Mechanisms of Cancer. This bibliography was generated on Cite This For Me on

  • Journal

    Green, J. A.

    Osimertinib—first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?

    2018 - Journal of Thoracic Disease

    In-text: (Green S3837-S3839)

    Your Bibliography: Green, John A. "Osimertinib—First Or Second Line For Epidermal Growth Factor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer?." Journal of Thoracic Disease 10.S33 (2018): S3837-S3839. Web.

  • Journal

    Ibrahim, M., Yadav, S., Ogunleye, F. and Zakalik, D.

    Male BRCA mutation carriers: clinical characteristics and cancer spectrum

    2018 - BMC Cancer

    In-text: (Ibrahim et al.)

    Your Bibliography: Ibrahim, Mohammed et al. "Male BRCA Mutation Carriers: Clinical Characteristics And Cancer Spectrum." BMC Cancer 18.1 (2018): n. pag. Web.

  • Journal

    Leonetti, A., Sharma, S., Minari, R., Perego, P., Geovannetti, E. and Tiseo, M.

    Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

    2019 - British Journal of Cancer

    In-text: (Leonetti et al. 725-737)

    Your Bibliography: Leonetti, Alessandro et al. "Resistance Mechanisms To Osimertinib In EGFR-Mutated Non-Small Cell Lung Cancer." British Journal of Cancer 121 (2019): 725-737. Web. 19 Nov. 2019.

  • Journal

    Nagano, T., Tachihara, M. and Nishimura, Y.

    Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

    2018 - Cells

    In-text: (Nagano, Tachihara and Nishimura 212)

    Your Bibliography: Nagano, Tatsuya, Motoko Tachihara, and Yoshihiro Nishimura. "Mechanism Of Resistance To Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors And A Potential Treatment Strategy." Cells 7.11 (2018): 212. Web.

  • Journal

    Ricciuti, B., Baglivo, S., Paglialunga, L., De Giglio, A., Bellezza, G., Chiari, R., Crinò, L. and Metro, G.

    Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy

    2017 - Therapeutic Advances in Medical Oncology

    In-text: (Ricciuti et al. 387-404)

    Your Bibliography: Ricciuti, Biagio et al. "Osimertinib In Patients With Advanced Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer: Rationale, Evidence And Place In Therapy." Therapeutic Advances in Medical Oncology 9.6 (2017): 387-404. Web.

  • Journal

    Soria, J., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C. and Cho, B.

    Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

    2018 - New England Journal of Medicine

    In-text: (Soria et al. 113-125)

    Your Bibliography: Soria, JC et al. "Osimertinib In Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.." New England Journal of Medicine 378.2 (2018): 113-125. Print.

  • Journal

    Tang, Z. and Lu, J.

    Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies

    2018 - Cancer Letters

    In-text: (Tang and Lu 242-246)

    Your Bibliography: Tang, Zheng-Hai, and Jin-Jian Lu. "Osimertinib Resistance In Non-Small Cell Lung Cancer: Mechanisms And Therapeutic Strategies." Cancer Letters 420 (2018): 242-246. Web.

Click here to start building your own bibliography
Keep on Citing!
Cite This For Me:
The Easiest Tool to Create your Bibliographies Online
Join Us!

Save Time and Improve Your Marks with Cite This For Me

10,587 students joined last month!

  • ✔ Save your bibliographies for longer
  • ✔ Super fast and accurate citation program
  • ✔ Save time when referencing
  • ✔ Make your student life easy and fun
  • ✔ Pay only once with our Forever plan
  • ✔ Use plagiarism checker
  • ✔ Create and edit multiple bibliographies
Join